Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease. It causes the left ventricle to thicken, the ...

The FDA has granted fast track designation to MT-125 for the treatment of patients with glioblastoma. The U.S. Food and Drug ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular ...

During the development of hypertrophy, cardiac myocytes increase organization of the sarcomere, a highly ordered contractile unit in striated muscle cells. Several hypertrophic agonists, such as ...

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is one of the best small cap stocks with the highest upside. H.C. Wainwright ...

Bristol Myers Squibb (BMS) on Wednesday announced the launch of Kopozgo (Mavacamten), an oral, selective cardiac myosin ...

In a phase 2b trial, danicamtiv, a novel cardiac myosin activator, was well tolerated and associated with improved heart ...

Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of ...

Bristol Myers Squibb launches Kopozgo in India for obstructive hypertrophic cardiomyopathy treatment, expanding therapeutic offerings.